By 2 Jun 2011
On 31 May 2011 Yungjin Pharm.'s asthma/COPD (Chronic obstructive pulmonary disease) medication development task was selected as "Ministry of Knowledge Economy, futurity industry leading technology enterprise"
Existing asthma/COPD medication is used to relieve symptoms for management purpose. If this task is successfully implemented and products are successfully released for treatment of asthma and chronic obstructive pulmonary disease, then it will be a groundbreaking new drug product of natural substance with relatively few adverse events.
Korean Market of asthma/COPD is about 219 billion KW and the world market is about 25trillion KW. If Yungjin successfully develop the product it is expected to sale over 10billion KW in domestic market in 3 years of release and in the case of entering the overseas market it expects to reach 50 billion KW in 3 years of product release.| distribué par | Ce noodl a été diffusé par Yungjin Pharm. Ind. Co. Ltd. et initialement mise en ligne sur le site http://www.yungjin.co.kr. La version originale est disponible ici. Ce noodl a été distribué par noodls dans son format d'origine et sans modification sur 2012-01-18 03:07:46 AM et restera accessible depuis ce lien permanent. Cette annonce est protégée par les règles du droit d'auteur et toute autre loi applicable, et son propriétaire est seul responsable de sa véracité et de son originalité. |
